Semaglutide intermediates' access qualification and speed competition

In the Semaglutide intermediates industry, in addition to directly cooperating with downstream customers to carry out contract customized production business, the most important business model is "R&D before sales". The characteristics of competition in the industry can be summarized as access qualification, speed competition, and technology competition, quality competition, and price competition in five aspects. This article is about the access qualification and speed competition of lab synthesized long-acting semaglutide intermediates. Here are some answers.

Here is the content list:

l Access qualification

l Speed competition

Access qualification

For the Semaglutide intermediates industry, the sales of products in the regulated market can not only bring stable profits to the company but also help the company establish a brand image and create a good reputation and reputation. However, for pharmaceutical high purity powder semaglutide intermediates products to enter the regulated market, in addition to qualified product quality, they must also have a good production environment, strict quality control, and standardized business operations, and produce standard product specification documents that meet the specifications. The on-site review and qualification approval of the market drug administration department can only sell API products to the regulated market. Therefore, having the ability to standardize the cGMP drug production management requirements in the market, being able to pass the on-site audit of the regulatory market drug administration department, and being able to compile and submit the DMF documents of Semaglutide intermediates is the most basic and core point for specialty API companies to enter the regulated market.

Speed competition

The ability to grab imitations is an important aspect of API stable 98% semaglutide intermediates market competition. Pharmaceutical patents mainly include compound patents, crystal form patents, process patents (including intermediates and preparation method patents), drug delivery system patents, and drug patents for different indications. The compound patent is generally the first to expire. Before the expiration of the compound patent, any generic drug preparations cannot be marketed; after the expiration of the compound patent, if the process patent of the original drug cannot be avoided, you must wait until the process patent of the original drug arrives. After the period, it can go on sale. Generally speaking, preparations for the listing of generic drugs by generic drug companies need to be deployed 5-10 years before the expiration of the target drug patent. The preliminary preparation includes project evaluation, product development, verification batch production, stability research, cGMP construction, and generic drug application. Wait for a series of work. As a supplier of Semaglutide intermediates, we strive to overcome the imitation process of glycolysis customized medical-grade semaglutide intermediates as soon as possible and provide downstream customers with high-quality Semaglutide intermediates products as soon as possible. And become its supplier and long-term partner in the research, occupy the market opportunity and a lot of market support.

Our official website is https://www.pu-kang.com/. If you are engaged in work related to Semaglutide intermediates or want to learn more about our company, you can communicate with us on the website. Our cost-effective products are well received by everyone.